To Get Full Access :

aBLA Filing Intelligence & Biosimilar Opportunity

Loqtorzi

Toripalimab-Tpzi
Anticancer
IV Infusion

Loqtorzi is an IV antibody used alongside other treatments for recurrent or metastatic nasopharyngeal carcinoma. It helps the immune system recognize and attack cancer cells.

Approval Date
27-Oct-23
Data Exclusivity Expiry
27-Oct-27
Market Exclusivity Expiry
27-Oct-35
Commercial snapshot

Market performance & projections

Revenue ($M)
329
CAGR (%)
-17.15%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
75
2027
115
2028
140
2029
155
2030
165
2031
175
2032
185
Molecule profile

Details & specifications

Molecule
Toripalimab-Tpzi
Innovator
COHERUS BIOSCIENCES
Dosage Form
IV Infusion
Strength
40 mg/mL
Therapeutic Category
Anticancer
Usage
To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?